Gilead CEO Daniel O’Day says the company will likely look for more deals like its $4.3 billion purchase of CymaBay Therapeutics over the next few years, rather than big buys costing tens of billions of dollars. “I believe that we’ll continue to look at smaller deals — think mid-single-digit billions on average — every few years,” O’Day said. The CymaBay move gave Gilead access to seladelpar, a late-stage primary biliary cholangitis treatment awaiting an FDA decision that’s slated for the middle of August.
Read the full article: Gilead’s M&A Appetite Is for Deals in the ‘Mid-Single-Digit Billions,’ CEO Says //
Source: https://endpts.com/gileads-ma-appetite-is-for-deals-in-the-mid-single-digit-billions-ceo-says/